Rare Cardiology News
Spotlight On
Hypopituitarism
Hypopituitarism refers to deficiency of one or more hormones produced by the anterior pituitary or released from the posterior pituitary
Prevalence
45/100,000
Age of Onset
ICD-10
E23.0
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
Rare View
Hypopituitarism is defined as the total or partial loss of anterior and posterior pituitary gland function that is caused by pituitary or hypothalamic disorders. The first known report of hypopituitarism was made by the German physician and pathologist Morris Simmonds.†
5 Facts you should know
FACT
Hypopituitarism refers to deficiency of one or more hormones produced by the anterior pituitary or released from the posterior pituitary
FACT
Onset can be acute or insidious, and the most common cause in adulthood is a pituitary adenoma, or treatment with pituitary surgery or radiotherapy
FACT
Most commonly, growth hormone (GH) is lost first, then gonadotropins, and finally thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH)
FACT
Pituitary dysfunction must be distinguished from anorexia nervosa , chronic liver disease, myotonia dystrophica, polyglandular autoimmune disease
FACT
Hypopituitarism is associated with excess mortality, a key risk factor being cortisol deficiency due to adrenocorticotropic hormone (ACTH) deficiency
Interest over time
Google searches
Hypopituitarism is also known as...
Hypopituitarism
Pituitary insufficiency
Common signs & symptoms
Symptoms vary depending on what hormones are insufficiently produced from the pituitary gland. The symptoms of hypopituitarism may resemble other conditions or medical problems. Common symptoms include:
Small penis in males
Very low blood sugar (hypoglycemia)
Slowed growth and short stature
Slowed sexual development
Prolonged jaundice at birth
Poor appetite
Weight loss or weight gain
Sensitivity to cold
Facial puffiness
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| Growth Hormone Replacement Therapy for Retried Professional Football Players | This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD). | Phase 2 | Recruiting | Biological: Growth Hormone|Other: Placebo | More Info |
| A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency | This is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. | Phase 3 | Recruiting | Drug: Lonapegsomatropin | More Info |
| A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is | This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children. | Phase 3 | Recruiting | Drug: Macimorelin|Diagnostic Test: Arginine|Diagnostic Test: Clonidine | More Info |
| A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency | A 38 week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. | Phase 3 | Recruiting | Drug: Lonapegsomatropin|Other: Placebo|Drug: Somatropin | More Info |
| Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) | he goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy | Phase 2 | Recruiting | Drug: LUM-201|Drug: rhGH Norditropin® pen (34 µg/kg) | More Info |
| A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day | The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day | Phase 3 | Active, not recruiting | Drug: Somapacitan|Drug: Norditropin® | More Info |
| A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial | A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. | Phase 3 | Active, not recruiting | Drug: TransCon hGH | More Info |
| Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency | The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. | Phase 2 | Recruiting | Drug: somapacitan|Drug: Norditropin® FlexPro® pen | More Info |
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | This will be an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency. | Phase 3 | Active, not recruiting | Drug: MOD-4023|Drug: Somatropin | More Info |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
|---|---|---|---|---|---|
| Growth Hormone | Human growth hormone | Phase 2 | Center for Neurological Studies | More Info | More Info |
| Macimorelin | Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. | Phase 3 | AEterna Zentaris | More Info | More Info |
| LUM-201 | LUM-201, also known as ibutamoren, is an investigational, once-daily, orally administered small molecule that promotes the secretion of Growth Hormone (GH) from the pituitary gland. | Phase 2 | Lumos Pharma | More Info | More Info |
| Somapacitan | Somapacitan is a human growth hormone analog | Phase 3 | Novo Nordisk A/S | More Info | More Info |
| TransCon hGH | TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body. | Phase 3 | Ascendis Pharma A/S | More Info | More Info |
| MOD-4023 | Long-Acting C-Terminal Peptide-Modified hGH | Phase 3 | OPKO Health, Inc. | More Info | More Info |
† Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 https://rarediseases.info.nih.gov